Wolfe Research initiated coverage on Repligen
$RGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Wolfe Research initiated coverage of Repligen with a rating of Peer Perform
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/24/2025 | $150.00 | Overweight | Barclays |
4/29/2025 | $160.00 | Peer Perform → Outperform | Wolfe Research |
3/18/2025 | $155.00 | In-line | Evercore ISI |
2/10/2025 | $200.00 | Buy | TD Cowen |
12/17/2024 | $165.00 | Hold | Canaccord Genuity |
11/14/2024 | Peer Perform | Wolfe Research | |
8/28/2024 | $180.00 | Overweight | Wells Fargo |
6/26/2024 | $180.00 → $155.00 | Hold → Buy | Deutsche Bank |
8-K - REPLIGEN CORP (0000730272) (Filer)
10-Q - REPLIGEN CORP (0000730272) (Filer)
8-K - REPLIGEN CORP (0000730272) (Filer)
4 - REPLIGEN CORP (0000730272) (Issuer)
4 - REPLIGEN CORP (0000730272) (Issuer)
4 - REPLIGEN CORP (0000730272) (Issuer)
Barclays initiated coverage of Repligen with a rating of Overweight and set a new price target of $150.00
Wolfe Research upgraded Repligen from Peer Perform to Outperform and set a new price target of $160.00
Evercore ISI initiated coverage of Repligen with a rating of In-line and set a new price target of $155.00
4 - REPLIGEN CORP (0000730272) (Issuer)
4 - REPLIGEN CORP (0000730272) (Issuer)
4 - REPLIGEN CORP (0000730272) (Issuer)